Work

A phase I study of HMPL-689, a selective oral phosphoinositide 3-kinase-delta inhibitor, in patients with relapsed or refractory lymphoma

Year: 2019

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz251.041

Authors: J. Cohen, R. Cordoba Mascunano, A.J.M. Ferreri, C. Yang, M. Kania, J. Kauh, N. Ghosh

Institutions: Emory University, Hospital Universitario Fundación Jiménez Díaz, IRCCS Ospedale San Raffaele, Levine Cancer Institute

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2978519085

FWCI:

Cites:

Cited by: 1

Related to: 10